Usage Information

Corticosteroids inhibit anti-IgE activities of specialized proresolving mediators on B cells from asthma patients
Nina Kim, … , Patricia J. Sime, Richard P. Phipps
Nina Kim, … , Patricia J. Sime, Richard P. Phipps
Published February 9, 2017
Citation Information: JCI Insight. 2017;2(3):e88588. https://doi.org/10.1172/jci.insight.88588.
View: Text | PDF
Research Article Immunology Inflammation Article has an altmetric score of 150

Corticosteroids inhibit anti-IgE activities of specialized proresolving mediators on B cells from asthma patients

Abstract

Specialized proresolving mediators (SPMs) promote the resolution of inflammation and exert beneficial effects in animal models of chronic inflammatory diseases, including asthma. Previously, we have shown that certain SPMs reduce IgE production in B cells from healthy individuals, which has a critical role in allergic asthma. Here, we investigated the effects of SPMs on B cell IgE production in asthma patients. Peripheral blood mononuclear cells from asthma patients were treated with 17-HDHA or RvD1, and IgE levels were measured. RvD1 and 17-HDHA dampened IgE production in B cells from most asthma patients, whereas B cells from a subset of patients taking oral steroids were refractory to SPM treatment. Molecular mechanisms underlying the interaction between corticosteroids and SPMs were investigated by treating B cells from nonasthmatic donors with corticosteroids in vitro. Corticosteroids blocked the inhibitory effects of 17-HDHA and RvD1 on B cell IgE production by abolishing the suppressive activity of these mediators on IgE class switching. Corticosteroids decreased the expression of transcriptional repressor Bcl-6 as well as its suppressive activity on epsilon germline transcription. We conclude that 17-HDHA and RvD1 can reduce IgE production in asthma patients not taking high doses of steroids but that corticosteroids interfere with the ability of B cells to respond to proresolving mediators.

Authors

Nina Kim, Thomas H. Thatcher, Patricia J. Sime, Richard P. Phipps

×

Usage data is cumulative from April 2024 through April 2025.

Usage JCI PMC
Text version 635 411
PDF 73 35
Figure 233 9
Table 46 0
Citation downloads 83 0
Totals 1,070 455
Total Views 1,525
(Click and drag on plot area to zoom in. Click legend items above to toggle)

Usage information is collected from two different sources: this site (JCI) and Pubmed Central (PMC). JCI information (compiled daily) shows human readership based on methods we employ to screen out robotic usage. PMC information (aggregated monthly) is also similarly screened of robotic usage.

Various methods are used to distinguish robotic usage. For example, Google automatically scans articles to add to its search index and identifies itself as robotic; other services might not clearly identify themselves as robotic, or they are new or unknown as robotic. Because this activity can be misinterpreted as human readership, data may be re-processed periodically to reflect an improved understanding of robotic activity. Because of these factors, readers should consider usage information illustrative but subject to change.

Advertisement